Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Financial Officer | September 18, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date September 18, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 382,323 |
Ending reported balance
After 2026-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-18 · Exercise / conversion · Acquired 6,250 · Balance 385,098 F1: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023. Row 2 · 2026-09-18 · Tax withholding · Disposed 2,775 · Balance 382,323 F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023.
F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 20:24 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,775 | $3.39 | $9,407.25 |
DisclosureSEC source: 0001470831-26-000895 · wk-form4_1790022287.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,323 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 18, 2026 Filed Sep 21, 2026 20:24 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000895 · wk-form4_1790022287.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 17:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 15,381 | $1.89 | $29,070.09 |
DisclosureSEC source: 0001470831-26-000175 · wk-form4_1771452283.xml · nonDerivative · entry 5 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,098 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 17:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 30,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000175 · wk-form4_1771452283.xml · nonDerivative · entry 4 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,863 | $1.89 | $3,521.07 |
DisclosureSEC source: 0001470831-26-000175 · wk-form4_1771452283.xml · nonDerivative · entry 3 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,479 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000175 · wk-form4_1771452283.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000175 · wk-form4_1771452283.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,342 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 16:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,775 | $3.32 | $9,213.00 |
DisclosureSEC source: 0001470831-25-000223 · wk-form4_1758312827.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,342 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 16:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-25-000223 · wk-form4_1758312827.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 130,600 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001662579-25-000016 · wk-form4_1739915682.xml · derivative · entry 4 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,600 Underlying: Common Stock · 130,600 shares Expires 2035-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 4,559 | $3.18 | $14,497.62 |
DisclosureSEC source: 0001662579-25-000016 · wk-form4_1739915682.xml · nonDerivative · entry 3 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,117 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 87,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000016 · wk-form4_1739915682.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,676 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 16:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,863 | $3.20 | $5,961.60 |
DisclosureSEC source: 0001662579-25-000016 · wk-form4_1739915682.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,576 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000103 · wk-form4_1731446246.xml · derivative · entry 3 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $6.04 | $6,656.08 |
DisclosureSEC source: 0001662579-24-000103 · wk-form4_1731446246.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,439 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 16:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000103 · wk-form4_1731446246.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,837 | $6.38 | $11,720.06 |
DisclosureSEC source: 0001662579-24-000086 · wk-form4_1726863223.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,791 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 17:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000082 · wk-form4_1726607540.xml · derivative · entry 3 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 17:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $6.36 | $4,203.96 |
DisclosureSEC source: 0001662579-24-000082 · wk-form4_1726607540.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,628 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 17:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000082 · wk-form4_1726607540.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 19:21 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000026 · wk-form4_1709943708.xml · derivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-02-13 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 19:21 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Disposition to issuerStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001662579-24-000026 · wk-form4_1709943708.xml · derivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2032-02-13 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 17:02 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 165,300 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001662579-24-000014 · wk-form4_1708034519.xml · derivative · entry 3 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,300 Underlying: Common Stock · 165,300 shares Expires 2034-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 17:02 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 36,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000014 · wk-form4_1708034519.xml · nonDerivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,039 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 17:02 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,301 | $6.53 | $8,495.53 |
DisclosureSEC source: 0001662579-24-000014 · wk-form4_1708034519.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,339 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:21 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 111,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000097 · wk-form4_1695165671.xml · derivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 111,000 shares Expires 2033-09-17 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:21 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000097 · wk-form4_1695165671.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,640 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on September 18, 2024, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.